University Of Montana

Inimmune's INI-4001 Advances to Human Cancer Trials in Australia

8 months ago

• Inimmune Corporation's INI-4001, a novel cancer treatment compound developed in collaboration with the University of Montana, is moving into human clinical trials in Australia. • The decision to conduct initial trials in Australia was influenced by faster trial initiation processes compared to the United States, with plans to expand to U.S. trials later. • INI-4001 is also being explored for potential use in a vaccine targeting heroin and fentanyl addiction, expanding its therapeutic applications beyond cancer. • The development of INI-4001 was supported by grant funding from the National Institutes of Health, highlighting the importance of research funding in advancing medical breakthroughs.

University of Montana's Cancer Immunotherapy Enters Phase 1 Human Trials

9 months ago

• Researchers at the University of Montana, in partnership with Inimmune, have advanced a novel cancer treatment into Phase 1 human clinical trials. • The immunotherapy drug, initially developed as an influenza vaccine, aims to retrain the body's immune system to target and destroy cancerous cells. • The treatment's development was supported by $33 million in grants and involves a multidisciplinary approach, from molecule design to safety testing. • The first patient in the trial is a 54-year-old woman with advanced breast cancer, marking a significant milestone for the research team.

Fentanyl Vaccine Poised for Clinical Trials, Offering Hope in Opioid Crisis

9 months ago

• A fentanyl vaccine developed at the University of Houston is set to enter clinical trials in mid-2025, aiming to prevent the opioid from reaching the brain. • The vaccine uses an adjuvant to stimulate the immune system to produce antibodies against fentanyl, preventing overdose by keeping the drug out of the brain. • Clinical trials will face challenges in recruiting participants with opioid use disorder and determining the vaccine's long-term effectiveness and optimal dosage. • Experts emphasize that the vaccine is not a standalone solution but a crucial addition to existing treatments like buprenorphine, potentially enhancing their efficacy.